News | June 22, 2022
MedC Biopharma partners with A2W Pharma to develop cannabinoid therapeutics
Bringing next-gen cannabinoid therapeutics to cancer patients
Bringing next-gen cannabinoid therapeutics to cancer patients
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Gilman will be responsible for all business development and portfolio strategy efforts globally.
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
Subscribe To Our Newsletter & Stay Updated
